Cancer Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics - Biologics Market Research

Cancer Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics
Published by : CHA Advances Reports
Pub Time: 2006/11
Price: $2750
Abstract
Cancer continues to pose a major health burden worldwide. Prevailing therapies are extremely limited in terms of safety, tolerability, and efficacy. Meanwhile, the morbidity and mortality associated with cancer is fueling interest in novel therapeutic approaches. Foremost among these are therapies that enhance the ability of the body' s own immune system to fight and destroy abnormal cancer cells. Anticancer vaccines and immune modulators, working in concert and as monotherapy, stole the show at ASCO last June, suggesting that after years of failure in the clinic their time has come. Cancer Immunotherapies and Vaccines: Pipeline Analysis and Competitive Dynamics , a new CHA Advances report, surveys and assesses recent developments in this highly promising avenue of cancer therapy.
Numerous biopharmaceutical companies are working to develop approaches that harness the body' s own immune system to fight cancer. Several monoclonal antibodies have already reached the market. This approach is sometimes referred to as passive immunotherapy. Our study focuses on active immunotherapies and vaccines that enhance the ability of the patient' s own immune system to fight cancer.
Cancer Immunotherapies and Vaccines begins by reviewing the pathophysiology, epidemiology, diagnosis, and current treatment options of eight major cancers targeted by companies developing immune modulating drugs and vaccines:
breast cancer
melanoma
colorectal cancer
pancreatic cancer
lung cancer
prostate cancer
lymphoma
renal cancer
While no active cancer immunotherapies (specifically targeted to a type of cancer) have reached the market, the most advanced example is Dendreon' s Provenge. Dendreon is submitting a rolling BLA (Biologics License Application) to the FDA for Provenge, for treatment of advanced hormone-refractory prostate cancer. Clinical trial data supporting this BLA, and available data on other immunotherapies and vaccines, are assessed in the report.
Cancer Immunotherapies and Vaccines also provides:
An explanation of R&D challenges in the development of cancer immunotherapies and vaccines
The various technical approaches being used to develop active cancer immunotherapies and vaccines
The many emerging immune-based therapies that are currently being evaluated in clinical trials for these eight cancers
Interviews with six senior executives from leading companies in the field of cancer immunotherapies and vaccines who discuss the progress, the challenges and hurdles, faced by researchers
Pipeline projects of over 35 companies, including discontinued projects
Thirteen SWOT charts (strengths, weaknesses, opportunities, threats) comparing the most promising immunotherapies and vaccines with standard therapy in 6 major cancers